Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 20/20 | 1.00 |
| ▸ | DRD2 | P14416 | 18/20 | 1.00 |
| ▸ | HTR1A | P08908 | 11/20 | 1.00 |
| ▸ | HTR2A | P28223 | 11/20 | 1.00 |
| ▸ | HTR2C | P28335 | 10/20 | 1.00 |
| ▸ | DRD4 | P21917 | 10/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19358699 | 1.00 | DRD3 (1.00) | DRD3DRD2HTR1AHTR2AHTR2C | |
| SCHEMBL29799765 | 1.00 | DRD3 (1.00) | DRD3DRD2HTR1AHTR2AHTR2C | |
| SCHEMBL29635932 | 1.00 | DRD3 (1.00) | DRD3DRD2HTR1AHTR2AHTR2C | |
| SCHEMBL29635915 | 1.00 | DRD3 (1.00) | DRD3DRD2HTR1AHTR2AHTR2C | |
| SCHEMBL29635959 | 1.00 | DRD3 (1.00) | DRD3DRD2HTR1AHTR2AHTR2C | |
| SCHEMBL19358701 | 1.00 | DRD3 (1.00) | DRD3DRD2HTR1AHTR2AHTR2C | |
| SCHEMBL19358670 | 0.91 | DRD2 (1.00) | DRD3DRD2HTR1AHTR2AHTR2C | |
| SCHEMBL19358700 | 0.91 | DRD2 (1.00) | DRD3DRD2HTR1AHTR2AHTR2C | |
| SCHEMBL19358671 | 0.91 | DRD2 (1.00) | DRD3DRD2HTR1AHTR2AHTR2C | |
| SCHEMBL29635942 | 0.91 | DRD2 (1.00) | DRD3DRD2HTR1AHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408084-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-12-12 | — | — | US | claimed |
| US-12097196-B2 | Dopamine D3 receptor selective antagonists/partial agonists and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-09-24 | — | — | US | claimed |
| US-20220265643-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-08-25 | — | — | US | claimed |
| US-11299476-B2 | Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-04-12 | — | — | US | claimed |
| US-20210346373-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-11-11 | — | — | US | claimed |
| EP-3849963-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | The United States of America, as Represented By the Secretary, Department of Health and Human Services (US) | 2021-07-21 | — | — | EP | claimed |
| EP-3429993-B1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | US HEALTH (US) | 2021-05-26 | — | — | EP | claimed |
| US-20200291000-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-09-17 | — | — | US | claimed |
| WO-2020055725-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-03-19 | — | — | WO | claimed |
| EP-3429993-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2019-01-23 | — | — | EP | claimed |
| WO-2017160552-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-09-21 | — | — | WO | claimed |
| EP-3848351-B1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | US HEALTH (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20240408084-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-12-12 | — | — | US | disclosed |
| US-12162861-B2 | Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-12-10 | — | — | US | disclosed |
| US-12097196-B2 | Dopamine D3 receptor selective antagonists/partial agonists and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-09-24 | — | — | US | disclosed |
| EP-3429993-B1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | US HEALTH (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3429993-B1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | US HEALTH (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20200291000-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-09-17 | — | — | US | disclosed |
| US-20200291000-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-09-17 | — | — | US | disclosed |
| WO-2017160552-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346373-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | OPRD1, OPRK1, DRD3 | DRD3 3/4885DRD2 6/4885HTR1A 54/4885 |
| US-12162861-B2 | Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof | DRD3, DRD2, SLC6A3 | DRD3 1/4885DRD2 2/4885HTR1A 45/4885 |
| US-20200291000-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | DRD3, DRD2, SLC6A3 | DRD3 1/4885DRD2 2/4885HTR1A 45/4885 |
| US-12097196-B2 | Dopamine D3 receptor selective antagonists/partial agonists and uses thereof | OPRD1, OPRK1, DRD3 | DRD3 3/4885DRD2 6/4885HTR1A 54/4885 |
| US-11299476-B2 | Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof | DRD3, DRD2, SLC6A3 | DRD3 1/4885DRD2 2/4885HTR1A 45/4885 |
| US-20240408084-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | DRD3, OPRD1, DRD2 | DRD3 1/4885DRD2 3/4885HTR1A 65/4885 |
| US-20220265643-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | OPRD1, OPRK1, DRD3 | DRD3 3/4885DRD2 6/4885HTR1A 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.